Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
Blueprint Medicines Corporation (NASDAQ:BPMC) will regain global commercialization and development rights to Gavreto (pralsetinib), excluding Greater China, following a…
Needham Maintains Buy on Blueprint Medicines, Lowers Price Target to $57
Needham analyst Ami Fadia maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and lowers the price target from $60 to $57.
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell
• RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022.
• Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year 2022.
Barclays Maintains Equal-Weight on Blueprint Medicines, Lowers Price Target to $44
Barclays analyst Peter Lawson maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and lowers the price target from $50 to $44.
Wells Fargo Upgrades Blueprint Medicines to Equal-Weight, Announces $41 Price Target
Wells Fargo analyst Derek Archila upgrades Blueprint Medicines (NASDAQ:BPMC) from Underweight to Equal-Weight and announces $41 price target.
Needham Initiates Coverage On Blueprint Medicines with Buy Rating, Announces Price Target of $60
Needham analyst Ami Fadia initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Buy rating and announces Price Target of $60.
Where Blueprint Medicines Stands With Analysts
Over the past 3 months, 8 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts…
Barclays Maintains Equal-Weight on Blueprint Medicines, Lowers Price Target to $53
Barclays analyst Peter Lawson maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and lowers the price target from $58 to $53.
Blueprint Medicines Submits Supplemental New Drug Application To FDA For AYVAKIT For Treatment Of Indolent Systemic Mastocytosis
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) for AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM).